ARS Pharmaceuticals (SPRY) Change in Receivables (2024 - 2026)

ARS Pharmaceuticals has disclosed Change in Receivables across 3 years of filings, most recently posting $839000.0 for Q1 2026.

• Change in Receivables for Q1 2026 came in at $839000.0, down 25.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $16.9 million (up 81.83% YoY), and the FY2025 annual result was $17.2 million, up 110.46% from the prior year.
• Change in Receivables came in at $839000.0 for Q1 2026 at ARS Pharmaceuticals, up from -$11.2 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $14.0 million in Q3 2025 to a low of -$11.2 million in Q4 2025.
• The 3-year median for Change in Receivables is $1.1 million (2025), against an average of $3.7 million.
• Peak annual rise in Change in Receivables reached 1712.03% in 2025, while the deepest fall reached 251.0% in 2025.
• ARS Pharmaceuticals' Change in Receivables stood at $7.4 million in 2024, then slumped by 251.0% to -$11.2 million in 2025, then soared by 107.51% to $839000.0 in 2026.
• The last three Change in Receivables figures came in at $839000.0 (Q1 2026), -$11.2 million (Q4 2025), and $14.0 million (Q3 2025), per Business Quant data.